<DOC>
	<DOCNO>NCT00289991</DOCNO>
	<brief_summary>Study compare antifungal prophylaxis Voriconazole Itraconazole subject Stem Cell Transplant . The success end point measure use evidence Infection , drug compliance survival .</brief_summary>
	<brief_title>Voriconazole Versus Itraconazole In Primary Prophylaxis Of Invasive Fungal Infection ( IFI ) In Subjects With Allogeneic Hematopoietic Stem Cell Transplants ( HSCT )</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Mycoses</mesh_term>
	<mesh_term>Itraconazole</mesh_term>
	<mesh_term>Hydroxyitraconazole</mesh_term>
	<mesh_term>Voriconazole</mesh_term>
	<criteria>Allogeneic HSCT acute leukemia ( AML , ALL myelodysplastic syndrome ) fail lymphoma therapy transformation CML Male Female 12 year great Possible , probable proven IFI study entry time 6 month prior study entry , define accord 'consensus criterion ' ( Ascioglu et al 2002 ) Previous history zygomycosis Anticipated survival le one month</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>